Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717451 | 0.90 | SYK (0.55) | SYK | |
| SCHEMBL2717457 | 0.89 | SYK (0.72) | SYKALKEGFR | |
| SCHEMBL2716506 | 0.83 | SYK (0.69) | SYK | |
| SCHEMBL735824 | 0.82 | SYK (1.00) | SYK | |
| SCHEMBL29865406 | 0.82 | SYK (1.00) | SYK | |
| SCHEMBL736185 | 0.76 | SYK (1.00) | SYK | |
| SCHEMBL29865795 | 0.76 | SYK (1.00) | SYK | |
| SCHEMBL763271 | 0.76 | SYK (0.88) | SYK | |
| SCHEMBL10271732 | 0.75 | SYK (0.49) | SYK | |
| SCHEMBL2716317 | 0.73 | SYK (0.67) | SYKALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317029-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | claimed |
| US-20130317029-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012061415-A1 | OXYPYRIMIDINES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317029-A1 | OXYPYRIMIDINES AS SYK MODULATORS | SYK, BTK, FYN | SYK 1/4885ALK 52/4885EGFR 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.